Company Description
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
The company’s product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain.
It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix.
The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products.
Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation.
Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2011 |
| IPO Date | Feb 11, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 930 |
| CEO | Robert Claypoole |
Contact Details
Address: 4721 Emperor Boulevard, Suite 100 Durham, North Carolina 27703 United States | |
| Phone | 919 474 6700 |
| Website | bioventus.com |
Stock Details
| Ticker Symbol | BVS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001665988 |
| CUSIP Number | 09075A108 |
| ISIN Number | US09075A1088 |
| Employer ID | 81-0980861 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert E. Claypoole | President, Chief Executive Officer and Director |
| Mark L. Singleton | Senior Vice President and Chief Financial Officer |
| Anthony D'Adamio J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Mike Crowe B.S., M.B.A. | Senior Vice President of Operations |
| David Crawford | Vice President of Investor Relations and Treasurer |
| Katrina J. Church J.D. | Senior Vice President and Chief Compliance Officer |
| Helen Leupold | Senior Vice President and Chief Human Resources Officer |
| Dave Venner | Senior Vice President and GM of Surgical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 4, 2025 | 8-K | Current Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| Jun 2, 2025 | SD | Form - SD |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | 144 | Filing |